PLEASANTON, Calif., May 6, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced its keynote speakers for the 2025 Veeva Commercial Summit, May 13-14 in Boston. Leading and emerging biopharmas will share innovations and strategies to drive more coordinated customer engagement through effective use of AI and alignment across data, content, and teams.
Veeva CEO Peter Gassner will headline the opening keynote, sharing Veeva's major initiative to add AI to the Vault Platform and Veeva applications, including ongoing innovations across Veeva Commercial Cloud and Veeva Data Cloud.
Keynote presenters will include experiences from:
ANI Pharmaceuticals, Gamida Cell, NewAmsterdam Pharma, Orchard Therapeutics, Sobi, and others will also share go-to-market best practices for emerging biotechs at launch and beyond.
"By connecting sales, marketing, and medical, field teams can seamlessly work together to drive more effective, customer-centric experiences," said Matt Farrell, president of Veeva Commercial Cloud. "We're excited to bring the industry together to share ideas and advancements in AI and data and help lead this next phase of unified engagement."
Veeva Commercial Summit is one of the largest industry events in North America for commercial and medical affairs leaders. Life sciences industry professionals can register and see the full agenda at veeva.com/Summit.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Matilde Macieira-Kaufmann
Veeva Systems
925-226-8821
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$282.90 |
Daily Change: | -5.08 -1.76 |
Daily Volume: | 1,420,671 |
Market Cap: | US$45.930B |
June 25, 2025 June 11, 2025 June 04, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load